Mereo Biopharma Group is a biopharmaceutical company focused on the development of therapeutics for rare diseases. Co.'s oncology and rare disease product candidates include: Setrusumab (BPS-804), which is an antibody designed to inhibit sclerostin, a protein that inhibits the activity of bone-forming cells; Alvelestat (MPH-966), which is an oral small molecule Co. is developing for the treatment of severe alpha-1 antitrypsin deficiency lung disease and bronchiolitis obliterans syndrome; and Etigilimab (MPH-313), which is an antibody against T-cell immunoreceptor with Ig and ITIM domains. The MREO average annual return since 2019 is shown above.
The Average Annual Return on the MREO average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MREO average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MREO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|